9
BioTech Navigator, August 1997
Selected Balance Sheet Data Year Ends Dec 31 (in millions)
Income Statement Year Ends Dec 31 (in millions)
Quarterly Income Statement (in millions)
Amgen Inc.
Company officials said
physicians are increasingly using Ne-
upogen because it provides more rapid
recovery of patients' white blood cells,
or neutropils, red blood cells and cells
that prevent bleeding (platelets) after
some forms of intensive chemotherapy
that suppress the body's ability to form
these blood cells. The faster blood cell
recovery reduces the time patients
who are risk for potentially severe sys-
temic infections such as anemia and
bleeding complications due to low cell
counts.
The FDA is not bound by the
panel's decision, but generally follows
its lead.
Q1 3-96
Q2 6-96
Q3 9-96
Q4 12-96
Revenue
EPS
476.9
.51
518.9
.64
533.3
.64
559.1
.64
Q1 3-97
Q2 6-97
Q3 9-97 (E)
Q4 12-97 (E)
Revenue
EPS
575.5
.65
620.5
.72
615.0
.71
615.0
.72
1996
1995
1994
Assets
Cash & Equivalent Assets
Inventory
Total Current Assets
Net property, Plant and Equipment
Total Assets
169.3
97.4
1,502.8
910.5
2,765.6
66.7
88.8
1,454.1
743.8
2,432.8
211.3
98.0
1115.6
665.3
1,994.1
Liabilities & Shareholders' Equity
Current Liabilities
Long Term Debt
Shareholders' Equity
Total Liabilities & Shareholders' Equity
642.9
59.0
1,026.9
2,765.6
583.8
177.2
864.8
2,432.8
536.4
183.4
1,274.3
1,994.1
1996
1995
1994
Revenue
Product Sales
Corporate Partner Revenue
Royalty Income
Total Revenue
2,088.2
109.9
41.7
2,239.8
1,818.6
85.2
36.1
1,939.9
1,549.6
70.4
27.9
1,647.9
Expenses
Cost of Goods Sold
Research & Development
Selling, Gen. & Admin.
Total Expenses
283.2
528.3
470.6
1,334.9
272.9
451.7
418.4
1,196.3
238.1
323.6
359.8
1,069.1
Income (loss) before Taxes
Net Income
Earnings per Share ($/share)
Shares outstanding (mil)
962.3
679.8
2.42
280.9
794.4
537.7
1.88
285.3
588.3
319.7
1.13
282.2
Valuation
Amgen is one of the few
biotech companies that has reached
utopia, that is, it has the ability to de-
velop, manufacture and market their
own therapeutics. Amgen's cash cow
are Neupogen and Epogen.
So far, the company has not
reported any significant setbacks on
any of its clinical trials and Amgen
continues and has the capability to
fund its own research and develop-
ment. Amgen has developed a num-
ber of potential therapeutics for its
product pipeline and is currently find-
ing new applications for its existing
marketed drugs. Amgen has been
slowly and steadily proven itself it can
perform.
For the past year, Amgen's
stock price has been in the hovering
in the range of the mid 50's to the
high 60's.
